Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1

Interventions

pembrolizumab 161Nivolumab 133Ipilimumab 78Cyclophosphamide 47Specimen Handling 43Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 29trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 21dabrafenib 20atezolizumab 19Radiotherapy 19Opdualag 19aldesleukin 18Radiosurgery 18CTLA-4 Antigen 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Bevacizumab 11Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GSK2141795 × Dermatologic × 1 year × Clear all
NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡